肽酰精氨酸脱亚氨酶2在创伤性脑损伤小鼠模型中的作用
该研究采用雄性小鼠(11–14周)控制性皮质撞击伤模型,每组n=5,比较野生型加创伤性脑损伤(WT-TBI)、PAD2敲除加创伤性脑损伤(PAD2-KO-TBI)、PAD4敲除加创伤性脑损伤(PAD4-KO-TBI)及PAD2/4双敲除加创伤性脑损伤(PAD2/4-DKO-TBI)组。伤后24小时脑切片染色显示,PAD2-KO-TBI和PAD2/4-DKO-TBI组损伤体积显著小于WT-TBI组(p=0.005和0.005)及PAD4-KO-TBI组(p=0.005和0.004);PAD4-KO-TBI与WT-TBI组间损伤体积无显著差异(p=0.880)。单核RNA测序及免疫荧光显示WT-TBI组PAD2上调(主要位于星形胶质细胞,与假手术组比较p=0.048),而PAD4未检出。PAD2-KO-TBI组伤后1–6天神经严重程度评分显著低于WT-TBI组(均p<0.05),Morris水迷宫测试提示WT-TBI组空间学习累积表现差于PAD2-KO-TBI组(p<0.05)。作者认为PAD2而非PAD4阻断可改善创伤性脑损伤结局,值得作为新型神经保护治疗靶点探索。
要点
- 雄性小鼠(11–14周)控制性皮质撞击伤模型中,PAD2-KO-TBI和PAD2/4-DKO-TBI组脑损伤体积显著小于WT-TBI组(p=0.005和0.005)。
- PAD4-KO-TBI与WT-TBI组脑损伤体积无显著差异(p=0.880),提示PAD4敲除未减小损伤体积。
- 伤后24小时WT-TBI组PAD2表达较假手术组上调(主要位于星形胶质细胞,p=0.048),PAD4未检出。
- PAD2-KO-TBI组伤后1–6天神经严重程度评分显著低于WT-TBI组(均p<0.05)。
- Morris水迷宫测试提示WT-TBI组空间学习累积表现差于PAD2-KO-TBI组(p<0.05)。
适用人群与场景
- 雄性小鼠(11–14周),采用控制性皮质撞击伤模型,每组n=5。
研究设计与关键结果
- 研究类型为小鼠创伤性脑损伤模型实验;每组n=5;实验分组为WT-TBI、PAD2-KO-TBI、PAD4-KO-TBI和PAD2/4-DKO-TBI。
- 伤后24小时脑切片染色显示,PAD2-KO-TBI和PAD2/4-DKO-TBI组损伤体积显著小于WT-TBI组(p=0.005和0.005),也显著小于PAD4-KO-TBI组(p=0.005和0.004)。
- PAD4-KO-TBI与WT-TBI组损伤体积无显著差异(p=0.880)。
- 伤后24小时单核RNA测序及免疫荧光显示WT-TBI组PAD2较假手术组上调(主要位于星形胶质细胞,p=0.048),PAD4未检出。
- PAD2-KO-TBI组伤后1–6天神经严重程度评分显著低于WT-TBI组(均p<0.05)。
- Morris水迷宫测试(伤后21–30天)显示WT-TBI组累积线索和非线索空间学习表现差于PAD2-KO-TBI组(p<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(小鼠创伤性脑损伤模型);原文未给出证据等级或推荐强度。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PAD2而非PAD4阻断可改善创伤性脑损伤结局,值得作为新型神经保护治疗靶点探索。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Traumatic brain injury (TBI) is among the leading causes of death and disability worldwide. Studies have linked peptidylarginine deiminases (PADs) with TBI outcomes. However, nonspecific PAD inhibition makes it difficult to decipher the exact role of specific PAD enzymes in neurotrauma. Since both PAD2 and PAD4 have been linked with neurodegeneration, we sought to clearly establish their roles in TBI.
METHODS: Male mice (11-14 weeks) were subjected to controlled cortical impact TBI (n = 5/group). Experimental groups included wild-type plus TBI (WT-TBI), PAD2 knockout plus TBI (PAD2-KO-TBI), PAD4 knockout plus TBI (PAD4-KO-TBI), and PAD2/4 double knockout plus TBI (PAD2/4-DKO-TBI). Twenty-four hours post-TBI, frozen brain sections were stained (Nissl and immunofluorescence) to determine lesion size and expression of PAD2 and PAD4. We also assessed the impact of PAD2-KO on neurologic severity scores (1-8 days post-TBI) and visuospatial learning using the Morris water maze test (21-30 days post-TBI).
RESULTS: Overall, PAD2-KO-TBI and PAD2/4-DKO-TBI animals displayed significantly smaller brain lesion sizes than WT-TBI (p = 0.005 and 0.005, respectively) and PAD4-KO-TBI (p = 0.005 and 0.004, respectively). However, there was no significant difference in lesion size between the PAD4-KO-TBI and WT-TBI (p = 0.880) groups. Analysis of archived snRNA-seq data and immunofluorescence staining 24 hours post-TBI showed upregulation of PAD2 (primarily in astrocytes) in WT-TBI compared with sham (p = 0.048), whereas PAD4 was undetectable. Overall, PAD2-KO-TBI had a significantly lower neurologic severity score on postinjury days 1 to 6 compared with WT-TBI (all p < 0.05) group. Moreover, Morris water maze test demonstrated that the cumulative cued and noncued spatial learning was worse in WT-TBI compared with PAD2-KO-TBI (p < 0.05) animals.
CONCLUSION: Our results suggest that PAD2, but not PAD4, blockade can improve outcomes following TBI, which justifies its exploration as a potential target for novel neuroprotective therapies.
参考来源
- Dawood ZS, Liggett MR, Wang B, et al. Role of peptidylarginine deiminase 2 in a murine model of traumatic brain injury. J Trauma Acute Care Surg. 2026. PMID: 41589731. doi:10.1097/TA.0000000000004813
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。